Загрузка...
The molecular basis of pharmacological chaperoning in human α-galactosidase
Fabry disease patients show a deficiency in the activity of the lysosomal enzyme α-galactosidase (α-GAL or α-Gal A). One proposed treatment for Fabry disease is pharmacological chaperone therapy, where a small molecule stabilizes the α-GAL protein, leading to increased enzymatic activity. Using enzy...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2011
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3246215/ https://ncbi.nlm.nih.gov/pubmed/22195554 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.chembiol.2011.10.012 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|